RBC Capital notes Addus HomeCare (ADUS) shares traded down almost 11% intraday after the company posted what the firm calls “solid” Q4 results and provided “extensive commentary” on the company’s Medicaid policy exposure. Addus has “minimal” Medicaid policy exposure and boasts a strong revenue growth outlook, bolstered by recent M&A, argues the firm, which would be buyers on weakness. RBC has an Outperform rating and $136 price target on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADUS:
- Addus Homecare: Strong Financial Performance and Strategic Growth Justify Buy Rating
- Addus HomeCare: Strong Financial Performance and Growth Potential Justify Buy Rating
- Addus HomeCare Reports Strong Q4 2024 Financial Results
- Addus HomeCare reports Q4 EPS $1.38, consensus $1.36
- Is ADUS a Buy, Before Earnings?